AstraZeneca (NASDAQ:AZN) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on November 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

AstraZeneca Stock Up 1.1%

Shares of NASDAQ AZN traded up $1.02 on Friday, hitting $91.63. The company had a trading volume of 3,807,915 shares, compared to its average volume of 5,199,066. The firm has a market capitalization of $284.17 billion, a P/E ratio of 30.44, a PEG ratio of 1.66 and a beta of 0.32. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $94.01. The business has a 50 day moving average of $87.46 and a two-hundred day moving average of $79.65.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The firm had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. During the same quarter in the prior year, the business earned $2.08 EPS. AstraZeneca’s quarterly revenue was up 12.0% compared to the same quarter last year. As a group, equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AstraZeneca

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Binnacle Investments Inc grew its stake in shares of AstraZeneca by 21.8% in the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock valued at $51,000 after buying an additional 118 shares in the last quarter. Chapin Davis Inc. lifted its position in shares of AstraZeneca by 3.3% in the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after buying an additional 120 shares during the last quarter. 44 Wealth Management LLC increased its holdings in shares of AstraZeneca by 0.7% during the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after acquiring an additional 124 shares during the last quarter. CoreCap Advisors LLC lifted its holdings in AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after purchasing an additional 125 shares during the last quarter. Finally, Highline Wealth Partners LLC grew its holdings in AstraZeneca by 32.0% during the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after purchasing an additional 129 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Jefferies Financial Group started coverage on AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating for the company. HSBC reiterated a “buy” rating and issued a $108.00 target price on shares of AstraZeneca in a research note on Wednesday, December 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price objective on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.